IDEAYA Biosciences (NASDAQ: IDYA) announced that its Phase 1/2 clinical trial evaluating IDE892, an MTA-cooperative PRMT5 inhibitor, has initiated Part ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE